Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

In today’s evolving market, investor attention is beginning to shift away from the dominant “Magnificent Seven” mega-cap ...

New York State Common Retirement Fund trimmed its Regeneron stake by 5% in Q1, selling over 6,800 shares worth millions.

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Amgen, with a price target of $300.00. The company’s shares closed last Friday at $295.27. Schott covers the ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...

We recently published Jim Cramer’s Fresh 14 Stocks & Thoughts About Market Performance. Cencora, Inc. (NYSE:COR) is one of ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.